- Report
- November 2022
- 104 Pages
Global
From €4474EUR$4,995USD£3,814GBP
- Report
- November 2019
Global
From €8952EUR$9,995USD£7,631GBP
- Report
- November 2024
- 93 Pages
Global
From €3500EUR$4,186USD£3,088GBP
- Report
- July 2024
- 94 Pages
Global
From €3500EUR$4,186USD£3,088GBP
- Report
- August 2023
- 90 Pages
Global
From €3500EUR$4,186USD£3,088GBP
- Report
- July 2024
- 156 Pages
Global
From €3807EUR$4,250USD£3,245GBP
- Book
- August 2010
- 480 Pages
The Cardiac Resynchronization Therapy Device (CRT-D) market is a subset of the larger cardiovascular device market. It is composed of devices used to treat heart failure, a condition in which the heart is unable to pump enough blood to meet the body's needs. CRT-D devices are designed to improve the coordination of the heart's pumping action, allowing it to pump more efficiently. These devices are typically implanted in the chest and are connected to the heart via wires.
CRT-D devices are used to treat a variety of heart conditions, including atrial fibrillation, ventricular tachycardia, and congestive heart failure. They are also used to reduce the risk of sudden cardiac death.
The CRT-D market is highly competitive, with a number of major players. These include Medtronic, Abbott, Boston Scientific, St. Jude Medical, Biotronik, and Sorin Group. Show Less Read more